Novartis and NHS England Agree on Kymriah Deal

NHS England and Novartis, manufacturer of the CAR-T therapy Kymriah, agreed on a deal that will make the drug available to the national health service’s cancer patients.

The deal came less than 10 days after the B-cell ALL treatment was approved for European marketing. The drug is part of a long-term plan by NHS to improve its cancer services.

“CAR-T therapy is a true game changer, and NHS cancer patients are now going to be amongst the first in the world to benefit,” said Simon Stevens, NHS England’s chief executive.